Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasm Metastasis 3Breast Neoplasms 3Sarcoma 2Neoplasms 2Brain Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Solid Tumor Malignancies 1Soft Tissue Neoplasms 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Pharyngeal Neoplasms 1Osteosarcoma 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Melanoma 1Lymphoma 1Lymphangioleiomyomatosis 1Leukemia, Lymphocytic, Chronic, B-Cell 1Head and Neck Neoplasms 1HTLV-I Infections 1Glioblastoma 1Erdheim-Chester Disease 1Endocrine Gland Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Rituximab 66Cyclophosphamide 52fludarabine phosphate 26fludarabine 22Filgrastim 21Vincristine 19Methotrexate 19Melphalan 19Doxorubicin 18Radiotherapy 17Etoposide 17Prednisone 16Tacrolimus 15Whole-Body Irradiation 14Mycophenolic Acid 14Cytarabine 14Peripheral Blood Stem Cell Transplantation 13Gemcitabine 13Cyclosporine 13Antilymphocyte Serum 13Lenalidomide 12Busulfan 11Bortezomib 11Granulocyte Colony-Stimulating Factor 9Alemtuzumab 9sargramostim 8Dexamethasone 8Cord Blood Stem Cell Transplantation 8pembrolizumab 7ibritumomab tiuxetan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma × Valproic Acid × Clear all
NCT00854581 2018-04-17

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

University of Miami

Phase 4 Terminated
13 enrolled 15 charts
LymphoidOther hematologic neoplasmOther neoplasm

Lymphoma, Precancerous Conditions, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡